Cagent Vascular Secures $15M Funding to Revolutionize PAD & CLTI Treatment with Groundbreaking Serration Balloon

Cagent Vascular, based in Wayne, PA, is celebrating a major milestone as it announces a successful raise of $15,000,000 in new funding. This significant investment highlights the growing confidence of investors in the company’s innovative approach to treating Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). At the heart of Cagent Vascular’s breakthrough is its novel angioplasty balloon featuring proprietary Serration Technology—a cutting-edge development designed specifically to address blocked arteries in the leg. The company’s flagship product, the Serranator PTA Serration Balloon Catheter, stands out as the first and only angioplasty balloon of its kind, reinventing conventional treatment methods with its unique serrated design that enhances effectiveness and safety during procedures. The freshly raised capital will be strategically dedicated to scaling up production, extending clinical trials, and broadening the company’s market presence both nationally and internationally. By bolstering its research and development efforts, Cagent Vascular aims to further refine its technology and support ongoing innovations that can dramatically improve patient outcomes. Additionally, the funds will fuel targeted marketing campaigns and help expand key partnerships within the medical community, ensuring that more patients have access to life-changing treatment options. This funding milestone not only reinforces Cagent Vascular’s commitment to advancing vascular care but also signals a promising future where groundbreaking technology meets critical medical needs, transforming the landscape of treatment for arterial diseases.